SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: muddphudd who wrote (268)5/2/2003 4:49:27 AM
From: nigel bates  Read Replies (1) of 371
 
Don't follow IMMU closely, but I do know they licensed it to Amgen in Dec 2000 -

...The agreement provides Amgen with rights to develop and commercialize
epratuzumab in North America and Australia. Amgen will also be responsible
for commercial manufacturing and will assume sponsorship of the U.S. INDs.
Amgen will also receive rights to second-generation CD22 products. In
addition, the agreement contemplates that the license could be expanded to
include rights to Immunomedics' radiolabeled CD22 antibody products.
The agreement includes an $18 million up-front payment to Immunomedics,
clinical milestone payments potentially totaling $65 million and royalties.
In addition, the agreement provides for one-time sales milestone payments
totaling $50 to $225 million if and when annual net sales reach $500 million
to $1 billion. Additional compensation would be paid to Immunomedics for each
second generation product developed by Amgen...

If you want more detail, I suggest you check the SEC filings.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News